Finalist
Launching a cure for Hepatitis C
Summary of work
It is currently estimated that there are 144,000 people living with hepatitis C in England. The cost to the NHS of hepatitis C-related liver disease is £156m resulting from the management of hepatitis C-liver complications and is rising by 10% annually.
Hepatitis C is not a popular subject for consumer journalists - in 2013 coverage in national papers tended to focus on `drug users’ and research projects with few mentions of other patient groups and existing treatments.
As well as media apathy one of the main hurdles to gaining positive coverage about hepatitis C during 2014 was the cost of new products coming to market and lack of understanding about their value to both patients and the NHS – this was also a potential barrier to any NICE/ Scottish Medicines Consortium recommendations.
However, through partnerships with third party organisations and KOLs, Health Unlimited cultivated strong relationships with journalists over an 18-month period to pave the way for the introduction of new treatments.
We secured 282 pieces of media coverage, averaging out to 5 articles per week. 79% of those that mentioned treatments spoke about Gilead-manufactured drugs. The media outreach also contributed to NHS England announcing a hepatitis C Early Access Scheme and the associated reimbursement for Gilead's Sovaldi.
Judges’ comments
Health Unlimited and Gilead were able to demonstrate how media relations positively impacted the access decisions via the exclusive Channel 4 reports - a rare achievement.
